Heidelberg Engineering Announces the CE-Marking of ANTERION
Heidelberg Engineering, the leader in diagnostic imaging known for the internationally-acclaimed SPECTRALIS ® retina and glaucoma platform, announces the CE-marking of ANTERION ® – an innovative platform designed to transform anterior segment diagnostics and workflow.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005442/en/
The new Heidelberg Engineering ANTERION® provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. (Graphic: Business Wire)
The new ANTERION provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. It is a single, workflow-efficient solution that brings together corneal topography and tomography, anterior segment metrics, axial length measurement and IOL calculation to transform the day-to-day routine of busy practices and clinics.
Heidelberg Engineering has leveraged its core OCT technologies in the development of the ANTERION, making the best use not only of swept-source OCT but also of patented tracking and composite imaging technologies to deliver exceptionally high-quality images of the anterior segment. Visual confirmation of all measurements with high-resolution swept-source OCT images establishes a new level of diagnostic confidence.
Prof. Oliver Findl, from the Hanusch Hospital in Vienna confirms the exceptional quality of the ANTERION images: “We had high-contrast and high-resolution OCT images of the entire anterior segment with little or no artifact movements. The scans were possible in eyes with different pathologies of the anterior and posterior segment.”
“ANTERION is a multimodal imaging platform, which can replace several devices, including corneal topographers and tomographers, pachymeters and biometers,” said Jacqueline Sousa Asam, MD, Medical Science Liaison at Heidelberg Engineering. “That leads to great improvement in the workflow and patient comfort in busy clinics, since moving patients can be unpleasant and time consuming. In addition, ANTERION displays information in very comprehensive layouts together with high-resolution OCT images, which also makes surgical planning faster and more efficient.”
Modular design: Imaging, Cornea, Cataract, and Metrics Apps
As the foundation of the ANTERION platform, the Imaging App focuses on the high-resolution visualization of the entire anterior segment, from the anterior surface of the cornea to the posterior surface of the lens. The other ANTERION Apps adjust to various clinical needs.
The Cornea App provides a comprehensive diagnostic solution to assess a patient’s individual corneal geometry. Corneal alterations can be diagnosed and monitored and the planning and evaluation of refractive surgery enhanced.
The Cataract App combines key measurements for cataract surgery planning: corneal analysis, anterior chamber depth, lens thickness, and axial length. The ability to assess total corneal power supports a more suitable IOL selection, while the integrated spheric and toric IOL calculator adds convenience to the pre-operative routine.
The Metrics App features swept-source OCT images with the anterior chamber displayed in a radial view. Predefined angle parameters can be determined and free-hand measurements can also be performed.
Swept-source and spectral domain OCT optimized at Heidelberg Engineering
Heidelberg Engineering has optimized swept-source OCT technology for anterior segment imaging on the new ANTERION and will continue to innovate with spectral domain OCT retinal imaging on the SPECTRALIS. Both imaging platforms aim to deliver the highest-quality images that empower eye care professionals to make confident diagnostic decisions that ultimately improve patient care.
Click on image or caption to download high resolution file
About ANTERION: www.anterion.com
About Heidelberg Engineering: www.heidelbergengineering.com/int/company
+49 (0)6221 64 63 317
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
SmartStream Steps Ahead with New Industry Digital Payments Solution22.10.2018 23:01 | Pressemelding
SmartStream Technologies, the financial Transaction Lifecycle Management (TLM®) solutions provider, today announced the launch of TLM Aurora, the next generation of Corona, the industry’s leading reconciliation platform – the first new module is designed to support the new industry standards in the digital payments world, by providing connectors to SWIFT GPI, RTGS, as well as Blockchain based networks, allowing for real-time operational control, proactive exception management and low TCO. TLM Aurora provides the new generation of integrated operational control for the digital marketplace. As transactions increase in variability, velocity and volume, the need for scalable, real-time, integrated reconciliations is greater than ever. TLM Aurora supports organisations in performing operations such as SWIFT and SEPA transfers, mobile, cash and card payments, digital currencies, settlements and reconciliations. The solution is agile enough to support the smallest of organisations and can be
CoreLogic to Acquire Symbility Solutions Inc.22.10.2018 22:12 | Pressemelding
CoreLogic (NYSE: CLGX), a leading global provider of property information, insight, analytics and data-enabled solutions, today announced the Company has entered into a definitive agreement to acquire the outstanding shares of Symbililty Solutions Inc. (“Symbility”) (TSX.V: SY) not already owned by CoreLogic. CoreLogic currently holds approximately a 28% ownership interest in Symbility. Symbility, founded in 2004, is a leading provider of subscription and cloud-based property insurance claims workflow solutions for the Property & Casualty insurance industry. Symbility also provides an extensive array of innovative enterprise mobile and application software solutions. The company is headquartered in Toronto, Canada and operates in the U.S., Canada, the United Kingdom, Germany, Netherlands, Australia and New Zealand. “Symbility expands our footprint in property and casualty insurance domestically and in key markets around the globe. Further scaling our insurance and international footpri
Pacific Drilling Awarded Contract for the Pacific Bora22.10.2018 21:00 | Pressemelding
Pacific Drilling S.A. (OTC: PACDQ) (“Pacific Drilling” or the “Company”) announced today that its deepwater drillship the Pacific Bora has been awarded a contract by Nigerian Agip Exploration Limited (a subsidiary of Eni SpA) for drilling operations in Nigeria. The term of the contract is for one firm well plus two additional option wells. The contract is expected to commence in mid to late November 2018 and firm contract backlog is estimated at $9 million. Pacific Drilling Chief Executive Officer Paul Reese commented: “On the heels of our previous announcement of new work for Pacific Santa Ana in Mauritania, we are pleased to have secured this contract for the Bora which reflects our substantial experience in Nigeria and our uninterrupted commitment to providing exceptional drilling services to our clients.” Currently offshore Abidjan, Côte d'Ivoire, the Pacific Bora is a sixth generation deepwater, dynamically-positioned drillship capable of operating in water depths up to 10,000 fee
ResMed Wins German Patent Infringement Case Against Fisher & Paykel22.10.2018 20:30 | Pressemelding
ResMed (NYSE: RMD) (ASX: RMD), the world’s leading tech-driven medical company and innovator in sleep apnea and respiratory care, today announced the results of a court and patent office ruling in Germany in ResMed’s favor. A trial court ruling from the Munich District Court states that the headgear used on two Fisher & Paykel CPAP masks – the Simplus full face and Eson 2 nasal mask – infringes ResMed patent EP 2 373 368 B1 in Germany. In a separate decision, the Opposition Division of the European Patent Office had already decided that the patent asserted against Fisher & Paykel is valid. Each decision may be appealed by Fisher & Paykel. “We applaud the Munich District Court for reaching this just finding, and are exploring all options in light of the fact that Fisher & Paykel is selling CPAP masks with headgear that infringes a valid ResMed patent in Germany,” said ResMed Chief Administrative Officer and Global General Counsel David Pendarvis. “We will continue to defend our intellec
Grand Prize Winner in $1.75M Water Abundance XPRIZE Announced at XPRIZE Visioneering 201822.10.2018 17:49 | Pressemelding
During Visioneering 2018, XPRIZE’s annual gathering of philanthropists and innovators to evaluate concepts for future competitions, the Foundation revealed the results of its latest, completed XPRIZE. The Skysource / Skywater Alliance was announced as the grand prize winner of the $1.75M Water Abundance XPRIZE, a two-year competition aimed at alleviating the global water crisis with energy-efficient technologies that harvest fresh water from thin air. In addition at Visioneering, five new prize concepts were evaluated with top honors going to a prize concept called “Coral Survival”, a prize designed to protect and restore coral reefs. This prize will move forward into the XPRIZE pipeline. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181022005795/en/ The Skysource / Skywater Alliance team, based in Venice Beach, California, wins the Water Abundance XPRIZE (Photo: Business Wire) The Water Abundance XPRIZE, powered by the Tat
Positive Trial Results with Filgotinib in Psoriatic Arthritis and Ankylosing Spondylitis Both Published in The Lancet22.10.2018 17:15 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that detailed results from two clinical trials evaluating filgotinib, an investigational, selective JAK1 inhibitor, for the treatment of psoriatic arthritis and ankylosing spondylitis were both published in The Lancet. The publication of the Phase 2 EQUATOR data also coincides with a plenary session presentation at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting. “The results of the EQUATOR and TORTUGA studies demonstrate that filgotinib improved the signs and symptoms of patients with psoriatic arthritis whose disease had not responded to prior therapies and independently, for those with ankylosing spondylitis,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences. “These findings represent an important step forward in our efforts to improve outcomes for people livin